Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Senior Management
Scientific Advisory Board
Corporate Governance
Programs
Xolatryp
Myocardial Ischemia and Arrhythmia Control
Stroke
Traumatic Brain Injury
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
6-Mar-2024
Proposed issue of securities - NYR
6-Mar-2024
Proposed issue of securities - NYR
4-Mar-2024
Trading Halt
28-Feb-2024
Nyrada CEO James Bonner interview with 180 Markets
28-Feb-2024
Significant Neuroprotection in NYR Preclinical Brain Injury
20-Feb-2024
Nyrada Half Year Results FY2024
20-Feb-2024
Appendix 4D and Half Year Report to 31 December 2023
19-Jan-2024
Amended and Restated Certificate of Incorporation and Bylaws
17-Jan-2024
Quarterly Activities Report and Appendix 4C
8-Dec-2023
Nyrada Receives A$3.54M R&D Tax Incentive Rebate
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Next
